股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | | 143,000,000 | | 增加 / 減少 (-) | | | | 0 | | USD | | | | | 本月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | | 143,000,000 ...

1. 章程 1.1 根據於 1999 年 3 月 11 日通過之書面決議案， 勵晶太平洋 集團有限公司 (「本公司」，連同其附屬公司統稱「本集團」) 董事會 (「董事會」) 成立 審核委員會 ( 「 本委員會 」 ) ，並通過採納本委員會之書面 職權範圍 (「職權範圍」)，清楚說明其權限及職責。 勵晶太平洋集團有限公司 - 審核委員會之職權範圍 2. 原則 3. 成員 -2- REGENT PACIFIC GROUP LIMITED 勵晶太平洋集團有限公司 （於開曼群島註冊成立之有限公司） 註冊辦事處 P.O. Box 309, Ugland House, South Church Street, Grand Cayman, KY1-1104 Cayman Islands 主要營業地點 香港中環皇后大道中 5 號衡怡大廈 8 樓 電話 (852) 2514 6111 傳真 (852) 2810 4792 網站 www.regentpac.com 電郵 info@regentpac.com 3.2 除彼等之董事酬金及許可之股權外，獨立非執行董事應獨立於管理層，且沒有 參與任何可能對彼等作為本委員會成員作出獨立判 ...

Core Viewpoint - Deep Longevity, Inc, a wholly-owned subsidiary of Lattice Biologics (00575.HK), is making a strategic move to enter the U.S. health market by appointing key executives [1] Group 1: Executive Appointments - Dylan Kay has been appointed as the Chief Business Officer for the U.S. [1] - Luke Shaffer has been appointed as the Vice President of Sales for the U.S. [1] - Both executives are set to officially start their roles on January 1, 2026 [1] Group 2: Market Entry Strategy - The appointments signify Deep Longevity's proactive approach to penetrate the largest health market globally, which is the United States [1] - The company plans to commence commercial operations in the first quarter of 2026 [1]

Core Insights - Deep Longevity, Inc. has appointed Dylan Kay as Chief Business Officer and Luke Shaffer as Vice President of Sales for the United States, effective January 1, 2026, marking its entry into the U.S. health market [1] - The company plans to launch its commercial operations in the first quarter of 2026, focusing on four key areas: corporate health and wellness programs, health insurance and risk-bearing entities, diagnostic laboratories and longevity clinics, and high-end consumer health platforms [1] - Deep Longevity aims to sign over 50 U.S. corporate clients by the end of 2026, positioning its aging clock technology at the center of the preventive healthcare revolution [2] Company Strategy - The appointments of Kay and Shaffer are strategic moves to leverage their extensive experience in health technology and corporate partnerships to drive growth [1][2] - Deep Longevity's clinically validated aging clocks, including BloodAge, EpigeneticAge, MindAge, BiometricAge, and the upcoming FaceAge, provide actionable insights across molecular, physiological, cognitive, and psychological aging dimensions [1] - The company's SaaS solutions enable employers and insurance companies to transition from passive disease care to proactive, quantifiable personalized longevity programs that can extend healthy lifespan and reduce long-term costs [1] Market Context - The U.S. healthcare expenditure is approximately $4.5 trillion annually, with 90% attributed to chronic diseases, highlighting the significant market opportunity for Deep Longevity's solutions [2] - The leadership of Kay and Shaffer is expected to transform emerging science into enterprise-level impact, aligning with the growing focus on preventive healthcare [2]

Core Insights - Deep Longevity, Inc. has appointed Dylan Kay as Chief Business Officer and Luke Shaffer as Vice President of Sales for the U.S. market, effective January 1, 2026, indicating a strategic move to penetrate the U.S. health market [1] Group 1 - The appointment of new executives signifies Deep Longevity's commitment to expanding its presence in the largest health market globally [1] - The company plans to initiate commercial operations in the first quarter of 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：���） 自願性更新營運情況 Deep Longevity於美國的業務擴展及 啟動二零二六年前委任主要高管 本公佈乃勵晶太平洋集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）按自願基準而作出，以知會本公司股東及潛在投資者下列 有關其營運的最新情況。 本 公 司 今 日 宣 佈，全 球 可 解 釋 人 工 智 能 驅 動 老 化 時 鐘 與 長 壽 科 學 的 領 導 者 Deep Longevity, Inc及其附屬公司（統稱「Deep Longevity」）委任Dylan Kay為 美利堅合眾國（「美國」）首席商務官及Luke Shaffer為美國銷售副總裁，二人均將於 二零二六年一月一日正式履新。 此次委聘標誌著Deep Longevity積極進駐全球最大的健康市場 － 美國，且已定於 二零二六年第一季度啟動商業 ...

Core Viewpoint - The stock price of Lattice Technology (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting the rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lattice Technology's stock has shown significant growth, with a current increase of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity in the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - Lijing Pacific (00575.HK) experienced a significant stock price increase, closing up over 12% and reaching a rise of 31.25% at 1.05 HKD per share, with a trading volume of 648,600 HKD [2] Summary by Category - **Stock Performance** - The stock price of Lijing Pacific rose by over 12% yesterday and is currently up 31.25% [2] - The closing price reached 1.05 HKD per share [2] - The total trading volume was 648,600 HKD [2]

Core Viewpoint - The stock of Lijing Pacific (00575) experienced a significant increase, rising over 12% yesterday and more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting a rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lijing Pacific's stock price has shown a remarkable increase, with a current rise of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity within the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market, which Deep Longevity aims to enter, is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - The stock price of Lattice Technology Pacific (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD [1] Company Summary - Lattice Technology Pacific announced that its wholly-owned subsidiary, Deep Longevity, a leader in AI-driven aging clocks and longevity science, will initiate an expansion plan into the U.S. market in the first quarter of next year [1] - This expansion will position Deep Longevity in the core of the largest and fastest-growing health market globally, which is currently valued at over 6.8 trillion USD [1]